<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193361</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-012</org_study_id>
    <nct_id>NCT01193361</nct_id>
  </id_info>
  <brief_title>Ph IIA Study (SOC +/- NS5B)</brief_title>
  <acronym>HEPCAT</acronym>
  <official_title>A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and
      efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the
      treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Formal analysis at week 4 (and upon occurrence)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Formal analysis at week 12 (and upon occurrence)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Formal analysis at week 24 post treatment (and upon occurrence)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Formal analysis at week 48 post treatment (and upon occurrence)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity, as determined by the proportion subjects with eRVR</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity, as determined by the proportion subjects with eRVR</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable HCV RNA</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with a 12-week SVR (SVR12) and 24-week SVR (SVR24), defined as undetectable HCV RNA at off treatment follow-up</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects with a 12-week SVR (SVR12) and 24-week SVR (SVR24), defined as undetectable HCV RNA at off treatment follow-up</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistant HCV variants associated with virologic failure</measure>
    <time_frame>End of treatment (Week 48) or upon early discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <description>Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response</description>
    <arm_group_label>Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <description>Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response</description>
    <arm_group_label>Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response</description>
    <arm_group_label>Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interferon alfa-2a</intervention_name>
    <description>Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response</description>
    <arm_group_label>Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_label>Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_label>Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response</description>
    <arm_group_label>Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_label>Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_label>Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects chronically infected with HCV genotype 1 as documented by: positive for
             anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to
             Screening, and positive for HCV RNA and anti-HCV antibody at Screening

          -  HCV RNA ≥ 10*5* IU/mL at Screening

          -  Less than 4 weeks total prior therapy with an IFN formulation (ie, IFNα, pegIFNα-2a),
             or RBV and no exposure to IFN or RBV within 24 weeks of Randomization

          -  Results of a biopsy obtained ≤ 24 months prior to Randomization showing no evidence of
             cirrhosis

          -  Body Mass Index (BMI) of 18 to 35 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
             at Screening

        Exclusion Criteria:

          -  Liver transplant recipients

          -  Documented or suspected HCC by imaging or liver biopsy

          -  Evidence of a medical condition associated with chronic liver disease other than HCV
             (such as but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver
             disease, alcoholic liver disease, toxin exposures)

          -  History of chronic hepatitis B virus (HBV) as documented by HBV serologies (eg.
             HBsAg-seropositive). Patients with resolved HBV infection may participate (eg.
             HBsAb-seropositive)

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claudia T. Martorell, Md, Llc</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology &amp; Hepatology, Pllc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The North Texas Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 9, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

